Initiating more efficacious therapies early in T2D treatment may improve long-term outcomes. Though associated with higher upfront costs, these therapies may reduce complication-related costs over time. Use of modern, efficacious therapies earlier in disease management may be a cost-effective strategy for healthcare payers.
Hoog et al. (Tue,) studied this question.